Medtronic Partners with Capital District Physicians’ Health Plan, Inc. (CDPHP) on Outcomes-based Agreement to Increase Quality and Improve Access to Critical Diabetes Care

August 14, 2019

DUBLIN - August 14, 2019 - Medtronic plc (NYSE:MDT), the global leader in medical technology, and Capital District Physicians' Health Plan, Inc. (CDPHP) today announced an innovative outcomes-based agreement for individuals with type 1 and type 2 diabetes that utilize a Medtronic insulin pump. Under the strategic partnership, Medtronic will provide eligible CDPHP members access to state-of-the-art technologies, supplies, and education and training support services to manage their diabetes. Additionally, a component of Medtronic's reimbursement will be tied to successfully meeting agreed upon clinical improvement thresholds for enrolled members – such as A1C reduction, increased Time in Range, and reduced hypoglycemic events.

Read more >

Real-World Data from Guardian(TM) Connect and Sugar.IQ(TM) Reveal Improved Diabetes Outcomes

June 10, 2019

DUBLIN and SAN FRANCISCO - June 10, 2019 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced real-world data on its Guardian(TM) Connect continuous glucose monitoring (CGM) system and Sugar.IQ(TM) diabetes assistant app presented at the 79th Scientific Sessions of the American Diabetes Association (ADA) Annual Meeting in San Francisco.

Read more >

MiniMedTM 670G System Real-World Data on 8 Million Patient Days Shows 71 Percent Time in Range Across All Age Groups

May 28, 2019

DUBLIN - May 28, 2019 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced real-world clinical outcomes for the MiniMed(TM) 670G system, which is being used by more than 180,000 people today. Data on nearly 8 million patient days1 showed an average Time in Range of 71 percent across all age groups. The advanced algorithm in the MiniMed 670G system automates and personalizes the delivery of basal insulin 24 hours a day and is the only commercially available technology in the world that proactively drives increased Time in Range by consistently guiding to the target of 120 mg/dL throughout the day-the lowest range offered in an automated insulin pump system. See animation to understand how the MiniMed 670G system works.

Read more >

New Value-Based Agreement Between Blue Cross and Blue Shield of Minnesota and Medtronic Leverages Diabetes Technology to Drive Positive Outcomes

April 8, 2019

MINNEAPOLIS and DUBLIN - Blue Cross and Blue Shield of Minnesota and Medtronic plc (NYSE:MDT), the global leader in medical technology, services and solutions, announce a new outcomes-based agreement that provides members of the Blue Cross and Blue Shield of Minnesota plan who live with diabetes improved access to the Guardian(TM) Connect smart Continuous Glucose Monitoring (CGM) system. The system will also now be made available through a member's pharmacy benefit, improving speed of delivery and may lower costs for members who use the device. Using the amount of time spent in a healthy glucose range as a key metric, value-based payments will be tied to the percentage of Time in Range achieved using the Guardian Connect system.

Read more >

New Prediction Feature for Hypoglycemia Now Available in Sugar.IQ(TM) Personal Diabetes Assistant App, Developed by Medtronic and IBM Watson Health

January 3, 2019

IQcast Feature Aims to Predict the Likelihood of a Low Glucose Event Up to Four Hours in Advance

DUBLIN and CAMBRIDGE, Mass. - January 3, 2019 - Medtronic plc (NYSE:MDT), the global leader in medical technology, services and solutions, and its strategic technology partner, IBM (NYSE:IBM) Watson Health, today announced a new feature for the Sugar.IQ(TM) personal diabetes assistant app called IQcast(TM). Using artificial intelligence (AI) technology from IBM Watson Health, the feature aims to predict the likelihood of an individual experiencing a low glucose event within an upcoming 1-4 hour window.

Read more >